Eli Lilly's next-generation weight-loss injectable retatrutide helped obesity patients lose 28% of their body weight on average in a late-stage trial. This more powerful drug may not be for everybody, but it helps Lilly build out a broader GLP-1 portfolio alongside injectable Zepbound and pill Foundayo. It's about options. Clear leader over Novo Nordisk.
Mon det passer at Novo er "second"
Mon det passer at Novo er "second"
21/5 2026 18:52 oneofakind 1
132405 Det handler mindre om procenter, men derimod om bivirkninger, der kan forhindre brugere i at benytte et produkt over en længere periode...
